CJC-1295 & Ipamorelin: Growth Hormone Secretagogue Research Guide
Growth researchAugust 19, 202612 min read
A comprehensive analysis of CJC-1295 and Ipamorelin in research settings, examining their mechanisms, synergistic potential, and application in laboratory models.
CJC-1295 is a synthetic GHRH analog that stimulates the transcription and release of growth hormone in research models.
CJC-1295 with DAC selectively binds to endogenous albumin, extending its half-life to 5.8-8.1 days.
Ipamorelin is a highly selective GHSR agonist that induces robust GH release without elevating ACTH, cortisol, or prolactin.
Combining a GHRH analog and a GHSR agonist produces a synergistic increase in total growth hormone and IGF-1 secretion.
CJC-1295 normalizes body weight and length in GHRH knockout mice when administered once daily.
All mentioned compounds are classified as Research Use Only (RUO) and are not approved for human therapeutic use.
The investigation of growth hormone secretagogues (GHS) represents a pivotal area in endocrinological and metabolic research. Among the most extensively studied compounds are the growth hormone-releasing hormone (GHRH) analogs and growth hormone secretagogue receptor (GHSR) agonists. Specifically, the combination of and has garnered significant attention in preclinical studies due to its unique synergistic mechanisms. This guide explores the foundational science, pharmacokinetic profiles, and laboratory applications of CJC-1295 Ipamorelin research.
CJC-1295
Ipamorelin
Featured In This Article
CJC-1295 / Ipamorelin
RESEARCH PEPTIDE
Highly purified synthetic peptide prepared for rigorous laboratory research.
$88.00
CJC-1295 No DAC
RESEARCH PEPTIDE
Highly purified synthetic peptide prepared for rigorous laboratory research.
$83.00
CJC-1295 with DAC
RESEARCH PEPTIDE
Highly purified synthetic peptide prepared for rigorous laboratory research.
$83.00
Ipamorelin
RESEARCH PEPTIDE
Highly purified synthetic peptide prepared for rigorous laboratory research.
$72.00
In laboratory environments, researchers study these peptides to understand their capacity to stimulate the anterior pituitary gland, thereby promoting the secretion of growth hormone (GH) without the rapid down-regulation or excessive prolactin spikes often associated with older secretagogues. Understanding the biochemical pathways of these compounds is critical for advancing research into cellular regeneration, metabolic regulation, and age-related endocrine decline in animal models.
Mechanism of Action in Research Models
To comprehend the efficacy of CJC-1295 Ipamorelin research, investigators must analyze the distinct yet complementary mechanisms through which these two peptides operate in vitro and in vivo.
The Role of CJC-1295 as a GHRH Analog
CJC-1295 is a synthetic analog of endogenous GHRH (Growth Hormone-Releasing Hormone). Its primary function in research subjects is to bind to the GHRH receptors on somatotroph cells in the anterior pituitary. This binding triggers a cyclic AMP (cAMP) dependent pathway, ultimately leading to the transcription and release of GH. Research demonstrates that CJC-1295, when administered once daily to GHRH knockout (GHRHKO) mice, normalizes body weight and length, indicating its profound efficacy in correcting severe GH deficiencies.
Ipamorelin: A Selective GHRP
Ipamorelin is a pentapeptide and a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR). Unlike earlier Growth Hormone Releasing Peptides (GHRPs) such as GHRP-2 or GHRP-6, Ipamorelin exhibits a highly specific binding profile. In preclinical research, it induces robust GH release without significantly elevating adrenocorticotropic hormone (ACTH), cortisol, or prolactin levels. This high selectivity makes it an ideal candidate for long-term observational studies in animal models where avoiding stress-hormone fluctuations is paramount.
When conducting CJC-1295 Ipamorelin research, investigators typically combine the two to mimic the body's natural pulsatile GH release while elevating the baseline trough levels, creating a synergistic multiplier effect on total GH secretion.
Understanding CJC-1295: With DAC vs. No DAC
A critical distinction in GHRH analog research is the presence or absence of the Drug Affinity Complex (DAC). The DAC modifies the peptide's pharmacokinetic profile significantly.
CJC-1295 No DAC (Modified GRF 1-29)
Often mislabeled simply as CJC-1295, CJC-1295 No DAC (properly termed Mod GRF 1-29) is a tetrasubstituted analog of GRF 1-29. It has a short half-life of approximately 30 minutes. In laboratory protocols, it is typically administered multiple times a day to induce acute, natural-mimicking pulses of GH release. It does not bind to albumin, ensuring rapid clearance from the system.
CJC-1295 with DAC
CJC-1295 with DAC features the addition of a maleimidopropionic acid complex. This complex allows the peptide to selectively and covalently bind to endogenous albumin post-injection. This binding extends its half-life dramatically. Subcutaneous administration of CJC-1295 in healthy adult research models resulted in sustained, dose-dependent increases in GH and IGF-1 levels, with an estimated half-life (t½) of 5.8 to 8.1 days. Mean IGF-1 levels remained elevated above baseline for up to 28 days following multiple doses.
Feature
CJC-1295 No DAC (Mod GRF 1-29)
CJC-1295 with DAC
Amino Acids
29
29 + DAC
Half-Life
~30 minutes
5.8 - 8.1 days
GH Release Pattern
Acute, pulsatile
Continuous, sustained elevation
Administration Frequency
Multiple times daily (typical)
1-2 times weekly (typical)
Comparative Analysis: Sermorelin and Tesamorelin
While CJC-1295 is highly effective, it is often compared to other GHRH analogs in research settings, notably Sermorelin and Tesamorelin.
Sermorelin: The shortest naturally occurring sequence of GHRH (first 29 amino acids) that retains full receptor binding functionality. It has a very brief half-life (under 15 minutes) and is utilized in studies requiring strict adherence to natural biological half-lives without extended stimulation. The World Anti-Doping Agency (WADA) monitors sermorelin and other synthetic analogs closely, underscoring their potent physiological effects.
Tesamorelin: Features a trans-3-hexenoic acid group attached to the N-terminus. It is highly resistant to dipeptidyl peptidase-4 (DPP-4) cleavage, giving it a longer half-life than Sermorelin but shorter than CJC-1295 with DAC. It is heavily researched for its unique ability to reduce visceral adipose tissue in lipodystrophy models.
The rationale behind utilizing a combined CJC-1295 / Ipamorelin formulation lies in their complementary mechanisms. CJC-1295 acts on the GHRH receptor to increase the amount of GH released per pulse and elevate the baseline. Simultaneously, Ipamorelin acts on the GHSR to increase the frequency and strength of the pulses while inhibiting somatostatin (the hormone responsible for halting GH release).
In animal studies, this dual-receptor approach yields a far greater net increase in serum IGF-1 levels compared to administering either peptide in isolation. Researchers investigating cellular senescence, bone density recovery, and lean muscle accretion frequently utilize this blend to maximize anabolic pathways without exhausting the somatotroph cells.
All peptides discussed, including CJC-1295 and Ipamorelin, are intended strictly for in-vitro and laboratory research purposes. They are not approved for human consumption or therapeutic use.
Laboratory Handling and Reconstitution
Proper handling is critical to maintaining the structural integrity of these peptides.
Storage: Lyophilized powder must be stored at -20°C for long-term stability. Once reconstituted, solutions should be kept refrigerated between 2°C and 8°C and used within 14-21 days.
Reconstitution: Researchers typically reconstitute these peptides using bacteriostatic water or sterile saline. The solvent should be introduced slowly, allowing it to flow down the side of the vial to prevent mechanical shearing of the delicate peptide bonds.
Handling: Avoid shaking the vial. Gentle swirling is recommended until the lyophilized puck is completely dissolved.
Regulatory Compliance and RUO Status
In the context of US laboratory regulations, CJC-1295, Ipamorelin, and other GHS compounds are classified as Research Use Only (RUO). This means they have not been evaluated or approved by the FDA for clinical diagnostics or therapeutic applications. Researchers must ensure that all procurement and utilization strictly align with institutional guidelines and federal regulations regarding RUO materials. Studies exploring the in vitro metabolism of these peptides, such as identifying 19 major in vitro metabolites of synthetic GHRH analogs, are crucial for advancing analytical detection methods.
By leveraging the unique properties of CJC-1295 and Ipamorelin, researchers continue to map the complex networks of the endocrine system, paving the way for future breakthroughs in metabolic science. For a broader comparison across the muscle-research peptide class, see our guide to the best peptides for muscle growth research.
Got Questions?
Frequently Asked Questions
The Drug Affinity Complex (DAC) allows the peptide to bind to endogenous albumin, drastically extending its half-life from approximately 30 minutes to up to 8 days in research models.
